Amgen/$AMGN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Amgen
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
- Ticker
- $AMGN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 31,500
- Headquarters
- Thousand Oaks, United States
- Website
- www.amgen.com
Amgen Metrics
BasicAdvanced
$253B
27.12
$17.26
0.42
$9.94
2.15%
Price and volume
Market cap
$253B
Beta
0.42
52-week high
$483.99
52-week low
$312.39
Average daily volume
2.7M
Dividend rate
$9.94
Financial strength
Current ratio
1.479
Quick ratio
1.013
Long term debt to equity
3.596
Total debt to equity
3.763
Dividend payout ratio (TTM)
57.14%
Interest coverage (TTM)
4.36%
Profitability
EBITDA (TTM)
17,632
Gross margin (TTM)
72.46%
Net profit margin (TTM)
24.14%
Operating margin (TTM)
31.75%
Effective tax rate (TTM)
15.03%
Revenue per employee (TTM)
$1,240,000
Management effectiveness
Return on assets (TTM)
8.29%
Return on equity (TTM)
78.35%
Valuation
Price to earnings (TTM)
27.121
Price to revenue (TTM)
6.492
Price to book
17.64
Price to tangible book (TTM)
-10.62
Price to free cash flow (TTM)
26.359
Free cash flow yield (TTM)
3.79%
Free cash flow per share (TTM)
17.759
Dividend yield (TTM)
2.12%
Forward dividend yield
2.15%
Growth
Revenue change (TTM)
8.15%
Earnings per share change (TTM)
33.45%
3-year revenue growth (CAGR)
13.18%
10-year revenue growth (CAGR)
5.60%
3-year earnings per share growth (CAGR)
7.08%
10-year earnings per share growth (CAGR)
5.62%
3-year dividend per share growth (CAGR)
6.07%
10-year dividend per share growth (CAGR)
10.12%
What the Analysts think about Amgen
Analyst ratings (Buy, Hold, Sell) for Amgen stock.
Analyst projections of the future price of Amgen stock.
Bulls say / Bears say
Amgen’s second-quarter revenue rose 10%, and it raised its 2026 outlook after strong drug sales. That points to solid near-term execution despite pressure on older products. (Reuters)
IMDELLTRA sales rose 115% to $288 million in the second quarter, and management cited Phase 3 results for a first-line maintenance combination. That gives the cancer drug room to become a larger growth driver if its use expands. (Amgen, StockAnalysis)
MariTide is being tested in Phase 3 for obesity and related conditions, including studies of less frequent dosing. If the drug proves effective and tolerable, that convenience could help Amgen compete in the weight-loss market. (Amgen, Healthcare Brew)
Biosimilar and pricing pressure is already cutting into established brands: second-quarter sales fell 32% for Prolia and 34% for Xgeva, while Otezla sales fell 21%. Further erosion could offset growth from newer medicines. (Amgen)
Tavneos faces a serious threat to its continued sales: the FDA has sought its withdrawal, while the pivotal study supporting approval was retracted amid concerns about data integrity and liver injuries. A forced withdrawal would remove a meaningful rare-disease product and add regulatory risk. (Bloomberg, The Lancet Rheumatology)
Data summarised monthly by Lightyear AI. Last updated on 1 Nov 2026.
Amgen Financial Performance
Revenues and expenses
Amgen Earnings Performance
Company profitability
Upcoming events
Amgen News
AllArticlesVideos
Funds containing Amgen
AllUSDEURGBP
Fund name | Fund size | $AMGN weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.3B | 8.32% |
iShares Nasdaq US Biotechnology$BTEC | $1.3B | 8.32% |
iShares Dow Jones Industrial Average€EXI3 | €315M | 5.28% |
iShares S&P 500 Health Care Sector€IUHE | €134M | 3.67% |
Invesco Health Care S&P US Select Sector£XLVP | $552M | 3.60% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.